Form 4: LENZ Therapeutics Director James W. McCollum Granted 13,500 Stock Options

LENZ Therapeutics, Inc. Director James W. McCollum was granted 13,500 stock options with an exercise price of $30, vesting fully on June 11, 2026.

Summary

• James W. McCollum, a Director of LENZ Therapeutics, Inc., was granted 13,500 stock options.
• The options have an exercise price of $30 per share.
• The options are set to vest 100% on June 11, 2026, provided Mr. McCollum continues to serve as an Outside Director.
• The options have an expiration date of June 10, 2035.
• This transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive event as it aligns the director's interests with shareholders and incentivizes long-term performance and retention. The amount is not excessively large to cause significant dilution concerns.

Positives

• The grant of stock options aligns the director's financial interests with those of shareholders, incentivizing long-term company performance and value creation.
• The vesting schedule encourages the retention of James W. McCollum as an Outside Director for at least another year.

Negatives

• The future exercise of these options could lead to minor dilution for existing shareholders, although the amount of shares is not exceptionally large.

Risks

• The vesting of the stock options is contingent on James W. McCollum's continued service as an Outside Director through June 11, 2026; if his service ceases before this date, the options will not vest.

Future Outlook

The vesting schedule indicates a future commitment for the director to remain with the company until June 11, 2026, to fully realize the benefit of the option grant, suggesting stability in board composition.

Industry Context

This filing represents a standard practice of compensating directors with equity, common across publicly traded companies to align leadership incentives with shareholder value creation and promote long-term commitment.

Corporate Governance

Related Party Transactions

• The grant of 13,500 stock options to James W. McCollum, a Director of LENZ Therapeutics, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: Benefit from aligned director incentives, potentially leading to improved long-term company performance, though there is a minor potential for future dilution upon option exercise.
• Director (James W. McCollum): Receives equity compensation, aligning personal financial interests with company performance and providing a long-term incentive.

Next Steps

• Continued service of James W. McCollum as an Outside Director until June 11, 2026, for the options to fully vest.
• Potential exercise of options by James W. McCollum before June 10, 2035, if the stock price is favorable.

Key Dates

Keywords

LENZ Therapeutics, LENZ, Stock Option, Form 4, Insider Transaction, Director Compensation, Equity Grant, James W. McCollum, SEC Filing, Rule 10b5-1